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Prostate cancer’s one-two punch
 
Tumors can avoid immune destruction despite being invaded
by tumor-specific CD8
 
 
 
 T cells. On page 1257, Bronte et
al. describe one way that prostate tumors subdue T cells—
they make two enzymes that combine forces to cripple T
cell signaling components.
Tumors use a variety of tactics to avoid attack by cytotoxic
CD8
 
 
 
 T cells; one is to establish an inhospitable environment
that inhibits T cell activation. In recent mouse studies,
Inducible nitric oxide synthase (NOS2) (brown) helps subdue CD8  
T cells in a human prostate tumor.
 
A single amino acid change in a tumor-
derived peptide results in the priming of a 
bigger and better T cell response upon 
vaccination, according to a study by Chen 
et al. on page 1243. Thus, results obtained 
with the original peptide, which is in phase 
I clinical trials as an anticancer vaccine, 
may be further enhanced by using the 
modified peptide.
Single amino acid changes in peptides 
can either enhance or inhibit activation of 
the T cells whose T cell receptors (TCRs) bind 
the peptide–HLA complex. Structural 
alterations in the HLA–peptide–TCR complex 
are thought to cause these functional 
changes, although how structural changes 
modify the signaling events inside the T cell 
is not completely understood.
To address this question, Chen et al. 
crystallized peptide–HLA–TCR complexes 
using either a wild-type tumor peptide or 
a variant peptide containing a cysteine to 
valine mutation at the COOH-terminal 
residue—a mutation they had previously 
shown to enhance killing of peptide-
 
coated target cells by cytotoxic T cells. The 
altered peptide bound to the HLA molecule 
more tightly and created a longer lasting, 
more snug fit between the peptide–HLA 
complex and the TCR.
This cozier interaction caused T cells to 
polarize their lytic granules toward target 
cells more rapidly and produce more 
cytokines upon target cell contact. The 
authors think that the tailored complex 
optimizes signaling events at the 
immunological synapse. Indeed, T cells 
stimulated with the altered peptide were less 
dependent on the CD8 coreceptor, which is 
necessary to stabilize some lower affinity 
TCR–HLA interactions.
Immunization of mice with the tighter 
fitting peptide primed more interferon-
 
 
 
–
producing T cells than were primed by the 
wild-type peptide, suggesting that vaccines 
that use the altered peptide vaccine may 
produce a superior T cell response.
Slight alterations in peptide sequence alter the peptide–HLA–TCR interaction 
and affect T cell priming.
 
myeloid suppressor cells infiltrated tumors and set up an
inhibitory environment, apparently by making two enzymes—
arginase and nitric oxide synthase 2 (NOS2).
Both enzymes can inhibit T cell functions independently.
But when expressed together, the enzyme duo triggers a cascade
of reactions that culminates in the production of peroxynitrite—
an oxidizing agent that nitrates tyrosine residues on proteins.
Tyrosine nitration blocks the tyrosine phosphorylation events
required for T cell activation and promotes apoptosis.
Increased expression of both arginase and NOS2 in
human prostate tumors has been reported, but their affect
on tumor-infiltrating T cells has never been directly studied.
Bronte and colleagues now show that CD8
 
 
 
 T cells in human
prostate tumors failed to up-regulate the activation markers
CD25 and CD69 in response to mitogenic stimulation.
Activation was restored when both arginase and NOS2
were inhibited. This occurred even without exogenous
stimulation, suggesting that the reawakened T cells were
responding to in situ–presented tumor antigens.
The need to inhibit both enzymes to reactivate the T
cells, and the presence of nitrotyrosine-positive cells in the
tumor tissue, pointed to tyrosine nitration as the key to
the T cell inhibition in this model. The authors are now
trying to understand what triggers the expression of these
enzymes in tumors and whether the same mechanisms operate
in other human tumors.
 
Perfecting peptide priming
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Polymerase pinch 
hitters
 
On page 1191, Delbos and colleagues 
provide the first proof that the error-
prone polymerase 
 
 
 
 (pol
 
 
 
) is 
responsible for mutations 
at A-T base pairs during somatic 
hypermutation (SHM) of 
immunoglobulin (Ig) genes in mice. 
But when pol
 
 
 
 is removed from mice, 
another sloppy enzyme, not 
previously thought to contribute to 
SHM, can fill in as a pinch hitter.
SHM generates high affinity 
antibodies in response to antigenic 
challenge; it does so by introducing 
point mutations into the antigen-
binding regions of B cell antibody 
genes. Mutations at C-G base pairs 
during SHM are the work of the 
enzyme AID (activation-induced 
cytidine deaminase), which turns 
cytosine into uracil. A-T mutations 
have been harder to explain. Error-
prone polymerases are thought be 
the culprits behind A-T mutation, but 
specific roles for these enzymes have 
been difficult to assign, as mice 
lacking individual polymerases have 
thus far shown no defects in SHM.
Pol
 
 
 
 has been the primary 
suspect charged with mutating A-T 
base pairs, as the pattern of errors 
made by pol
 
 
 
 in vitro is reminiscent 
of that seen in mutated Ig loci. In 
addition, humans lacking pol
 
 
 
 have 
fewer A-T mutations in their Ig genes 
than normal. Delbos et al. now 
solidify the evidence by showing that 
elimination of pol
 
 
 
 in mice decreases 
Ig gene mutations at A-T base pairs.
The few A-T mutations that 
occurred in the absence of pol
 
 
 
—to 
the authors’ surprise—bore the 
signature of another polymerase, 
pol
 
 
 
, which does not normally 
meddle in SHM. The authors suggest 
that the mismatch repair protein 
complex MSH2–MSH6, recently 
shown to recruit pol
 
 
 
 to AID-induced 
U-G mismatches, may in pol
 
 
 
’s 
absence instead bind pol
 
 
 
. The pol
 
 
 
 
would then cause mutations at 
nearby A-T sites.
 
Healing with hyaluronan
 
Specialized T cells in the skin lay a sugary foundation
for macrophage migration into wounds, according
to a study on page 1269. Jameson and colleagues
show that the absence of dendritic epidermal 
 
  
 
 T
cells (DETCs) removes the impetus for skin cells to
secrete hyaluronan, an extracellular glycan that is
required for macrophage entry into wounds. With-
out macrophages, wounds can’t heal.
Wound healing is initiated when DETCs
recognize an unknown antigen on damaged skin
cells. Neutrophils and, later, macrophages migrate to
the wound site; both cell types are needed for
complete healing. This group had previously shown
that wound repair breaks down in the absence of
DETCs due to a lack of keratinocyte growth factors
FGF-7 and FGF-10, which are produced by DETCs
in wounds and stimulate keratinocyte regeneration.
Jameson et al. noted that nonhealing wounds
in DETC-deficient mice were less inflamed than
normal wounds. They now show that, though neutrophils arrived at the wound on
schedule, macrophages showed up late. The macrophage tardiness could be traced
back to the lack of FGF-7. In normal wounds, FGF-7 was found to trigger the
production of hyaluronan by neighboring keratinocytes and hyaluronan was
needed to recruit macrophages. If hyaluronan (or FGF-7) was added back to the
wounds, the macrophages returned and healing was restored.
Impaired wound healing is prevalent in patients with diabetes and rheumatoid
arthritis. The authors hope to investigate whether impaired DETC function may be
to blame in these human diseases.
Efficient macrophage migration 
into wounded skin requires 
hyaluronan (blue).
 
Neutrophil–DC close encounters
 
On page 1281, van Gisbergen and colleagues describe for the first time a direct interaction 
between neutrophils and dendritic cells (DCs). The event triggers DC activation, primes T 
helper 1 (Th1) cells, and may help explain why Th1 responses to some pathogens are impaired 
in the absence of neutrophils.
Neutrophils have been shown to influence the priming of Th1 responses indirectly: they 
secrete cytokines and chemokines that promote Th1 responses and recruit DCs into infected 
tissues. But van Gisbergen et al. now show that neutrophils don’t always keep their distance. 
They can interact with DCs directly through binding of the C-type lectin DC-SIGN on DCs to 
specific carbohydrate structures on the neutrophil integrin Mac-1.
Neutrophil–DC binding triggered activation of the DCs as measured by DC up-regulation 
of CD86 and secretion of interleukin-12. But this only happened if the neutrophils were first 
activated, suggesting that DC activation only occurs in an inflammatory setting. Neutrophil-
activated DCs went on to prime interferon-
 
 
 
–producing Th1 cells.
One possible consequence of this interaction, the authors speculate, might be transfer of 
antigens from the neutrophils to the DCs, although this idea remains to be tested. Another 
open question is whether neutrophils receive signals as part of the relationship with DCs.
The dendritic cell lectin DC-SIGN (red) binds to carbohydrate structures on the neutrophil 
integrin Mac-1 (green).
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